This book systematically describes the achievements and current situation of in vitro diagnostic (IVD) industry in China. It consists of twelve parts, including the overview on the IVD industry in China in 2021, hot technologies and products of IVD industry, academic, technological and product development in the field of IVD, such as biochemical diagnosis, immune-diagnosis, point-of-care testing, molecular diagnosis, blood and body fluid diagnosis, microbial detection, laboratory assembly line, etc. In this second edition, the new contents added include the development of new coronavirus molecular diagnostic products, flight mass spectrometry, tandem mass spectrometry, tumor markers, ELISA immune reagents, autoimmune diagnostics, concomitant diagnosis, fecal and intestinal microecology detection, pathological diagnosis, raw materials for in vitro diagnostic reagents, standard substances and quality controls for in vitro diagnostic reagents, etc., making the content of the whole book more novel and rich. This book is compiled by an editorial committee composed of well-known entrepreneurs, experts and professors in IVD industry in China. It is a reference book for practitioners of IVD industry, medical laboratory and medical staffs all over the world.

​This authoritative volume examines the major laws, regulations and guidelines related to pharmaceutical product development in China. With a focus on patent, clinical and registration strategies, the book helps Western companies introduce their clinical drugs to the Chinese market, determine a strategic path and bridge the gap for regulatory and legal differences between China and the Western world. For a better understanding of the drug registration process, it explores the differences between the China Food and Drug Administration (CFDA)—including its regulations and registration procedures—and those of the Western world. The volume discusses disparities between China's application requirements compared to Western standards to make it easier for companies to prepare their application packages. It also provides detailed commentary on CFDA guidelines in reference to clinical trial (IND) and market application (NDA) requirements. Overall, this book offers guidance for Western companies aspiring to expand into China’s pharmaceutical market in hopes that they may gain a fundamental understanding of its rules and complexities in order to ensure a smooth transition and prevent future issues.

Companion and Complementary Diagnostics: From Biomarker Discovery to Clinical Implementation provides readers with in-depth insights into the individual steps in the development of companion diagnostic assays, from the early biomarker discovery phase straight through to final regulatory approval. Further, the clinical implementation of companion diagnostic testing in the clinic is also discussed. As the development of predictive or selective biomarker assays linked to specific drugs is substantially increasing, this book offers comprehensive information on this quickly-evolving area of biomedicine. It is an essential resource for those in academic institutions, hospitals and pharma, and biotech and diagnostic commercial companies. - Covers all aspects, from biomarker discovery, to development and regulatory approval - Explains the "how to" aspects of companion diagnostics - Incorporates information on the entire process, allowing for easier and deeper understanding of the topic

Concomitant with a rapid increase in population and an unprecedented growth of the economy, China came to endure an alarming level of environmental damgae. In response, environmental legislation was tightened and massive environmental projects were initiated. As a result, China's environment and ecosystems are begining to recover. At the same time, the country is continuing on its growth path, making an above-average contriubtion to the global emission of greenhouse gases, not least becuase of the heavy use of coal as a source of energy. The world's second-largest economy aims to halt this trend by rapidly building sustainable and clean energy resources and has committed itself to being carbon neutral by 2060. in this process, "beautiful China" intends to become the global role model of a "digital civilization" based on science and technology. This book describes the stakeholders, programs, and achievements along this path and provides an outlook on pertinent developments in the years to come.

Every year there are 8.8 million new active cases and nearly two million deaths worldwide from tuberculosis (about 5,000 every day), mostly in the poorest communities of the developing world. One third of the world's population has latent TB which may later develop into an active form of the disease, and it has also become the leading cause of death among people with HIV. Multidrug-resistance is also a growing problem. A key challenge for the public health community is to be able to effectively diagnose patients so that valuable resources and medicines are not wasted on misdiagnosis and repeat treatments. This report, written by an international network of researchers and policy experts, examines the global market for TB diagnostics available for active disease, latent infection, drug resistance and treatment response. It provides a sound basis for diagnostics development suitable for various levels of health systems in industrialised and developing countries.

This book systematically describes the achievements and current situation of in vitro diagnostic (IVD) industry in China. It consists of eight parts, including the overview on the IVD industry in China in 2019, hot technologies and products of IVD industry, academic, technological and product development in the field of IVD, such as biochemical diagnosis, immune-diagnosis, molecular diagnosis, blood and body fluid diagnosis, microbial detection, point-of-care testing, laboratory assembly line, etc. This book is compiled by an editorial committee composed of well-known entrepreneurs, experts and professors in IVD industry in China. It is a reference book for practitioners of IVD industry, medical laboratory and medical staffs all over the world.

This reference book provides promising strategies for investing in the promising healthcare and nursing sector of the People's Republic of China. The Chinese healthcare sector is growing steadily, and the Chinese government has recognized that the participation of foreign investors is essential to improve and develop the Chinese healthcare system, especially in metropolitan areas. This opens up opportunities and possibilities for foreign healthcare providers, whose investments are increasingly welcomed and supported by the Chinese government. The book presents ways to make safe and profitable investments in the Chinese healthcare market: from the construction of new hospitals and nursing homes to the introduction of the necessary medical equipment and the acquisition and recruitment of qualified staff. In particular, the legal framework conditions are highlighted. This book is a translation of the original German 1st edition Investitionen im chinesischen Gesundheits- und Pflegesektor by Björn Etgen, published by Springer Fachmedien Wiesbaden GmbH, part of Springer Nature in 2019. The translation was done with the help of artificial intelligence (machine translation by the service DeepL.com). A subsequent human revision was done primarily in terms of content, so that the book will read stylistically differently from a conventional translation. Springer Nature works continuously to further the development of tools for the production of books and on the related technologies to support the authors.

This book presents an overview of up-converting phosphor (UCP), including UCP preparation, development of the rapid detection strips and UCP industrialization. It also discusses the wide clinical applications of this technology, such as in food poisoning, infectious diseases, drug-abuse and disaster rescue, where rapid point-of-care testing is often critical. Conventional testing methods are mainly based on gold immunochromatography, which relies heavily on results being read with the naked eye. However, up-converting phosphor technology (UPT) employs UCP particles as labels for rapid target detection. Unlike other conventional fluorescence techniques, UCP is excited by infrared light and emitted visible light. This anti-stokes phenomenon provides this special label with significant advantages, including zero background detection, high resistance to environmental influences (e.g. pH, salts, sample contamination), high sensitivity and quantitative detection. Systematically summarizing UCP technology and its wide applications, this book is a valuable resource for researchers and technicians in the field.

In the fourth instalment of his ‘Belt and Road Initiative’ series, Gerald Chan provides a critical analysis of China’s vaccine diplomacy. Locating it within China’s wider infrastructure development strategy, Chan deploys geo-developmentalism as a theoretical tool to analyse its contribution to a new global health order, particularly with the pandemic pushing the country to the forefront of vaccine exportation.

本书是《新发展阶段企业的机遇与创新——蓝迪平台企业发展报告（2021）》的英文版，主要内容涉及：介绍蓝迪企业平台围绕产业和企业发展的相关工作；回顾蓝迪平台企业及项目情况，重点介绍了2021年挖掘、培育、推介的15家重点企业的情况；介绍“一带一路”背景下蓝迪平台企业的产业布局及相关情况；介绍蓝迪国际智库团队建设的情况，并附上蓝迪平台企业名单。